Korsana Biosciences, Inc.
KRSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001755237
No open-market purchases or sales by Korsana Biosciences, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $11.2M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $1.44B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 21
- 13F valueReported value at the end of Q2 2026
- $11.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $2.07M
- +3.7% year over year
- Net income, FY2025
- -$3.53M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $3.53M (170.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 167.4K
- Shares sold short
- Change
- +143.6K
- +603.1% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding KRSA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KRSA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Korsana Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 25, 2024 (view filing)4:05 PM ET | Nov 21 | 4 days | Slate Path Capital LP and 1 other10% Owner | SSaleCommon Stock, no par value | −357.9K | $1.55 | −$555.1K | −100.0%0 after | |
| Aug 11, 2023 (view filing) | Aug 9 | 2 days | McGuire TerranceDirector | SSale | −8 | $3.40 | −$27.2 | −100.0%0 after |
Top 10 13F holders, Q2 2026
See all 21 holdersThe largest institutional positions in Korsana Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kalehua Capital Management LLC | 1,651,350 | $5.60M | 3.22% | +1,651,350 | New |
| FMR LLC | 649,547 | $2.20M | 0.00% | +644,807+13,603.5% | Added |
| Balyasny Asset Management LLC | 317,511 | $1.08M | 0.00% | +317,511 | New |
| ADAR1 Capital Management, LLC | 298,757 | $1.01M | 0.05% | +298,757 | New |
| Braidwell LP | 156,890 | $531.9K | 0.02% | +156,890 | New |
| Citadel Advisors LLC | 59,795 | $202.7K | 0.00% | +41,534+227.4% | Added |
| Geode Capital Management, LLC | 45,850 | $155.5K | 0.00% | −38,700−45.8% | Reduced |
| Vanguard Capital Management LLC | 30,915 | $104.8K | 0.00% | +14,778+91.6% | Added |
| Rangeley Capital, LLC | 24,310 | $82.4K | 0.08% | +24,310 | New |
| HRT Financial LP | 22,054 | $74.0K | 0.00% | +22,054 | New |
Holders of 5% or more of KRSA
See all 10 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Korsana Biosciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 13D | 19.99%9.11M shares | New | Sep 11, 20261 filing | Sep 11, 2026 | SEC |
| Hecht Peter M | 13D/A | 19.40%910.2K shares | −8.50 ppfrom 27.90% | May 14, 20219 filings | Jul 20, 2026 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13D | 9.90%4.55M shares | New | Sep 15, 20261 filing | Sep 15, 2026 | SEC |
| Balyasny Asset Management LLC | 13G | 7.33%317.5K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| ADAR1 Capital Management, LLC | 13G | 7.00%298.8K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |